NCT04650581 2026-04-13
FINER
Canadian Cancer Trials Group
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT04060862 2024-11-08
IPATunity150
Hoffmann-La Roche
Phase 1 Terminated
NCT03800836 2024-10-30
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT04177108 2024-03-27
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03337724 2024-03-12
IPATunity130
Hoffmann-La Roche
Phase 3 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT03840200 2023-10-30
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Hoffmann-La Roche
Phase 1 Completed
NCT02162719 2021-03-10
LOTUS
Genentech, Inc.
Phase 2 Completed
NCT02301988 2018-10-17
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
Genentech, Inc.
Phase 2 Completed